Erratum: Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases (ACS Nano (2013) 7 DOI: 10.1021/nn400669r);Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases

ACS Nano

Volumn 7, Issue 5, 2013, Pages 4221-4232

  Liu, Tracy W ^a,b   MacDonald, Thomas D ^a,c   Jin, Cheng S ^a,c   Gold, Joseph M ^a,b   Bristow, Robert G ^a,b,d   Wilson, Brian C ^a,b   Zheng, Gang ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

orthotopic; porphysomes; prostate cancer

Indexed keywords

MEDICAL IMAGING; NANOPARTICLES; PATHOLOGY; TUMORS; UROLOGY;

METASTATIC CANCERS; MULTI-MODAL NANOPARTICLES; ORGANIC NANOPARTICLES; ORTHOTOPIC; PORPHYSOMES; PROSTATE CANCERS; PROSTATE-CANCER IMAGING; TREATMENT RESPONSE;

DISEASES;

COPPER; DIAGNOSTIC AGENT; NANOPARTICLE; PORPHYRIN;

ANIMAL; ARTICLE; CHEMISTRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; LIPID BILAYER; MALE; METABOLISM; MICROMETASTASIS; MOUSE; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; SCINTISCANNING; TIME; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; COPPER RADIOISOTOPES; HUMANS; LIPID BILAYERS; MALE; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASM MICROMETASTASIS; PORPHYRINS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 84878310997     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn401788g     Document Type: Erratum

References (70)

1. Ward, J. F., 3rd; Rewcastle, J. C.; Ukimura, O.; Gill, I. S. Focal Therapy for the Treatment of Localized Prostate Cancer: A Potential Therapeutic Paradigm Shift Awaiting Better Imaging Curr. Opin. Urol. 2012, 22, 104-108
2. Lindner, U.; Trachtenberg, J.; Lawrentschuk, N. Focal Therapy in Prostate Cancer: Modalities, Findings and Future Considerations Nat. Rev. Urol. 2010, 7, 562-571
3. Schroder, F. H.; Hugosson, J.; Roobol, M. J.; Tammela, T. L.; Ciatto, S.; Nelen, V.; Kwiatkowski, M.; Lujan, M.; Lilja, H.; Zappa, M. Screening and Prostate-Cancer Mortality in a Randomized European Study N. Engl. J. Med. 2009, 360, 1320-1328
4. Hoffman, R. M. Screening for Prostate Cancer N. Engl. J. Med. 2011, 365, 2013-2019
5. Bahn, D. K.; Silverman, P.; Lee, F., Sr.; Badalament, R.; Bahn, E. D.; Rewcastle, J. C. Focal Prostate Cryoablation: Initial Results Show Cancer Control and Potency Preservation J. Endourol. 2006, 20, 688-692
6. Ahmed, H. U.; Freeman, A.; Kirkham, A.; Sahu, M.; Scott, R.; Allen, C.; Van der Meulen, J.; Emberton, M. Focal Therapy for Localized Prostate Cancer: A Phase I/II Trial J. Urol. 2011, 185, 1246-1254
7. Lindner, U.; Weersink, R. A.; Haider, M. A.; Gertner, M. R.; Davidson, S. R.; Atri, M.; Wilson, B. C.; Fenster, A.; Trachtenberg, J. Image Guided Photothermal Focal Therapy for Localized Prostate Cancer: Phase I Trial J. Urol. 2009, 182, 1371-1377
8. Lindner, U.; Lawrentschuk, N.; Schatloff, O.; Trachtenberg, J.; Lindner, A. Evolution from Active Surveillance to Focal Therapy in the Management of Prostate Cancer Future Oncol. 2011, 7, 775-787
9. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer Statistics, 2009 CA Cancer J. Clin. 2009, 59, 225-249
10. Cooperberg, M. R.; Carroll, P. R.; Klotz, L. Active Surveillance for Prostate Cancer: Progress and Promise J. Clin. Oncol. 2011, 29, 3669-3676
11. Turkbey, B.; Pinto, P. A.; Choyke, P. L. Imaging Techniques for Prostate Cancer: Implications for Focal Therapy Nat. Rev. Urol. 2009, 6, 191-203
12. Halpern, E. J.; Frauscher, F.; Rosenberg, M.; Gomella, L. G. Directed Biopsy During Contrast-Enhanced Sonography of the Prostate Am. J. Roentgenol. 2002, 178, 915-919
13. Loch, T.; Leuschner, I.; Genberg, C.; Weichert-Jacobsen, K.; Kuppers, F.; Yfantis, E.; Evans, M.; Tsarev, V.; Stockle, M. Artificial Neural Network Analysis (ANNA) of Prostatic Transrectal Ultrasound Prostate 1999, 39, 198-204
14. Mirowitz, S. A.; Brown, J. J.; Heiken, J. P. Evaluation of the Prostate and Prostatic Carcinoma with Gadolinium-Enhanced Endorectal Coil MR Imaging Radiology 1993, 186, 153-157
15. Gibbs, P.; Tozer, D. J.; Liney, G. P.; Turnbull, L. W. Comparison of Quantitative T2 Mapping and Diffusion-Weighted Imaging in the Normal and Pathologic Prostate Magn. Reson. Med. 2001, 46, 1054-1058
16. Kurhanewicz, J.; Vigneron, D.; Carroll, P.; Coakley, F. Multiparametric Magnetic Resonance Imaging in Prostate Cancer: Present and Future Curr. Opin. Urol. 2008, 18, 71-77
17. Weissleder, R.; Pittet, M. J. Imaging in the Era of Molecular Oncology Nature 2008, 452, 580-589
18. Solomon, M.; Liu, Y.; Berezin, M. Y.; Achilefu, S. Optical Imaging in Cancer Research: Basic Principles, Tumor Detection, and Therapeutic Monitoring Med. Prin. Pract. 2011, 20, 397-415
19. Liu, Y.; Bauer, A. Q.; Akers, W. J.; Sudlow, G.; Liang, K.; Shen, D.; Berezin, M. Y.; Culver, J. P.; Achilefu, S. Hands-Free, Wireless Goggles for Near-Infrared Fluorescence and Real-Time Image-Guided Surgery Surgery 2011, 149, 689-698
20. Liu, Y.; Solomon, M.; Achilefu, S. Perspectives and Potential Applications of Nanomedicine in Breast and Prostate Cancer Med. Res. Rev. 2013, 33, 3-32
21. Vallabhajosula, S. Molecular Imaging: Radiopharmaceuticals for PET and SPECT; Springer-Verlag: Berlin; New York, 2009; p xix.
22. Gambhir, S. S. Molecular Imaging of Cancer with Positron Emission Tomography Nat. Rev. Cancer 2002, 2, 683-693
23. Ntziachristos, V.; Ripoll, J.; Wang, L. H. V.; Weissleder, R. Looking and Listening to Light: The Evolution of Whole-Body Photonic Imaging Nat. Biotechnol. 2005, 23, 313-320
24. Louie, A. Multimodality Imaging Probes: Design and Challenges Chem. Rev. 2010, 110, 3146-3195
25. Jokerst, J. V.; Gambhir, S. S. Molecular Imaging with Theranostic Nanoparticles Acc. Chem. Res. 2011, 44, 1050-1060
26. Nystrom, A. M.; Wooley, K. L. The Importance of Chemistry in Creating Well-Defined Nanoscopic Embedded Therapeutics: Devices Capable of the Dual Functions of Imaging and Therapy Acc. Chem. Res. 2011, 44, 969-978
27. Ali, Z.; Abbasi, A. Z.; Zhang, F.; Arosio, P.; Lascialfari, A.; Casula, M. F.; Wenk, A.; Kreyling, W.; Plapper, R.; Seidel, M. Multifunctional Nanoparticles for Dual Imaging Anal. Chem. 2011, 83, 2877-2882
28. Policard, A. Etudes Sur Les Aspects Offerts Par Des Tumeurs Experimentales Examinees a La Lumiere De Woods C. R. Soc. Biol. 1924, 91
29. 64Cu Labelling of Hematoporphyrin Derivative for Non-Invasive In Vivo Measurements of Tumour Uptake Prog. Clin. Biol. Res. 1984, 170, 629-636
30. Wilson, B. C.; Firnau, G.; Jeeves, W. P.; Brown, K. L.; Burns-McCormick, D. M. Chromatographic Analysis and Tissue Distribution of Radiocopper-Labelled Haematoporphyrin Derivatives Laser Med. Sci. 1988, 3, 71-80
31. Bases, R.; Brodie, S. S.; Rubenfeld, S. Attempts at Tumor Localization Using Cu 64-Labeled Copper Porphyrins Cancer 1958, 11, 259-263
32. Wrenn, F. R., Jr.; Good, M. L.; Handler, P. The Use of Positron-Emitting Radioisotopes for the Localization of Brain Tumors Science 1951, 113, 525-527
33. Shi, J.; Liu, T. W.; Chen, J.; Green, D.; Jaffray, D.; Wilson, B. C.; Wang, F.; Zheng, G. Transforming a Targeted Porphyrin Theranostic Agent into a PET Imaging Probe for Cancer Theranostics 2011, 1, 363-370
34. Lovell, J. F.; Jin, C. S.; Huynh, E.; Jin, H.; Kim, C.; Rubinstein, J. L.; Chan, W. C.; Cao, W.; Wang, L. V.; Zheng, G. Porphysome Nanovesicles Generated by Porphyrin Bilayers for Use as Multimodal Biophotonic Contrast Agents Nat. Mater. 2011, 10, 324-332
35. 64-Labeled Organic Nanoparticles as Radiotracers Angew. Chem., Int. Ed. 2012, 51, 13128-13131
36. Lovell, J. F.; Jin, C. S.; Huynh, E.; Macdonald, T. D.; Cao, W.; Zheng, G. Enzymatic Regioselection for the Synthesis and Biodegradation of Porphysome Nanovesicles Angew. Chem., Int. Ed. 2012, 51, 2429-2433
37. Huynh, E.; Zheng, G. Engineering Multifunctional Nanoparticles: All-in-One Versus One-for-All. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2013, doi: 10.1002/wnan.1217.
38. Biju, V.; Itoh, T.; Anas, A.; Sujith, A.; Ishikawa, M. Semiconductor Quantum Dots and Metal Nanoparticles: Syntheses, Optical Properties, and Biological Applications Anal. Bioanal. Chem. 2008, 391, 2469-2495
39. Longmire, M.; Choyke, P. L.; Kobayashi, H. Clearance Properties of Nano-Sized Particles and Molecules as Imaging Agents: Considerations and Caveats Nanomedicine 2008, 3, 703-717
40. Ballou, B.; Ernst, L. A.; Andreko, S.; Harper, T.; Fitzpatrick, J. A.; Waggoner, A. S.; Bruchez, M. P. Sentinel Lymph Node Imaging Using Quantum Dots in Mouse Tumor Models Bioconjugate Chem. 2007, 18, 389-396
41. Weissleder, R.; Stark, D. D.; Engelstad, B. L.; Bacon, B. R.; Compton, C. C.; White, D. L.; Jacobs, P.; Lewis, J. Superparamagnetic Iron Oxide: Pharmacokinetics and Toxicity Am. J. Roentgenol. 1989, 152, 167-173
42. Wang, S. Y.; Kim, G.; Lee, Y. E. K.; Hah, H. J.; Ethirajan, M.; Pandey, R. K.; Kopelman, R. Multifunctional Biodegradable Polyacrylamide Nanocarriers for Cancer Theranostics-a "See and Treat" Strategy ACS Nano 2012, 6, 6843-6851
43. Bigler, S. A.; Deering, R. E.; Brawer, M. K. Comparison of Microscopic Vascularity in Benign and Malignant Prostate Tissue Hum. Pathol. 1993, 24, 220-226
44. Matsumura, Y.; Maeda, H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs Cancer Res. 1986, 46, 6387-6392
45. Davis, M. E.; Chen, Z.; Shin, D. M. Nanoparticle Therapeutics: An Emerging Treatment Modality for Cancer Nat. Rev. Drug Discovery 2008, 7, 771-782
46. LeRoy, B. E.; Thudi, N. K.; Nadella, M. V.; Toribio, R. E.; Tannehill-Gregg, S. H.; van Bokhoven, A.; Davis, D.; Corn, S.; Rosol, T. J. New Bone Formation and Osteolysis by a Metastatic, Highly Invasive Canine Prostate Carcinoma Xenograft Prostate 2006, 66, 1213-1222
47. Wei, J. T.; Dunn, R. L.; Sandler, H. M.; McLaughlin, P. W.; Montie, J. E.; Litwin, M. S.; Nyquist, L.; Sanda, M. G. Comprehensive Comparison of Health-Related Quality of Life after Contemporary Therapies for Localized Prostate Cancer J. Clin. Oncol. 2002, 20, 557-566
48. Sanda, M. G.; Dunn, R. L.; Michalski, J.; Sandler, H. M.; Northouse, L.; Hembroff, L.; Lin, X.; Greenfield, T. K.; Litwin, M. S.; Saigal, C. S. Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors N. Engl. J. Med 2008, 358, 1250-1261
49. Ma, B.; Li, G. L.; Kanter, P.; Lamonica, D.; Grossman, Z.; Pandey, R. K. Bifunctional HPPH-N2S2-Tc-99m Conjugates as Tumor Imaging Agents: Synthesis and Biodistribution Studies J. Porphyrins Phthalocyanines 2003, 7, 500-507
50. Liu, T. W.; Akens, M. K.; Chen, J.; Wise-Milestone, L.; Wilson, B. C.; Zheng, G. Imaging of Specific Activation of Photodynamic Molecular Beacons in Breast Cancer Vertebral Metastases Bioconjugate Chem. 2011, 22, 1021-1030
51. Washington, S. L.; Bonham, M.; Whitson, J. M.; Cowan, J. E.; Carroll, P. R. Transrectal Ultrasonography-Guided Biopsy Does Not Reliably Identify Dominant Cancer Location in Men with Low-Risk Prostate Cancer BJU Int. 2011, 110, 50-55
52. van den Berg, N. S.; van Leeuwen, F. W. B.; van der Poel, H. G. Fluorescence Guidance in Urologic Surgery Curr. Opin. Urol. 2012, 22, 109-120
53. Rocco, B.; Cozzi, G.; Spinelli, M. G.; Grasso, A.; Varisco, D.; Coelho, R. F.; Patel, V. R. Current Status of Salvage Robot-Assisted Laparoscopic Prostatectomy for Radiorecurrent Prostate Cancer Curr. Urol. Rep. 2012, 13, 195-201
54. Freedland, S. J. Screening, Risk Assessment, and the Approach to Therapy in Patients with Prostate Cancer Cancer 2011, 117, 1123-1135
55. Rouvière, O.; Vitry, T.; Lyonnet, D. Imaging of Prostate Cancer Local Recurrences: Why and How? Eur. Radiol. 2010, 20, 1254-1266
56. Mundy, G. R. Mechanisms of Bone Metastasis Cancer 1997, 80, 1546-1556
57. Pinski, J.; Dorff, T. B. Prostate Cancer Metastases to Bone: Pathophysiology, Pain Management, and the Promise of Targeted Therapy Eur. J. Cancer 2005, 41, 932-940
58. Eaton, C. L.; Coleman, R. E. Pathophysiology of Bone Metastases from Prostate Cancer and the Role of Bisphosphonates in Treatment Cancer Treat. Rev. 2003, 29, 189-198
59. Abrahamsson, P.-A. Pathophysiology of Bone Metastases in Prostate Cancer Eur. Urol. Suppl. 2004, 3, 3-9
60. Aus, G.; Abbou, C. C.; Bolla, M.; Heidenreich, A.; Schmid, H. P.; Van Poppel, H.; Wolff, J.; Zattoni, F. Eau Guidelines on Prostate Cancer Eur. Urol. 2005, 48, 546-551
61. Rosenthal, D. I. Radiologic Diagnosis of Bone Metastases Cancer 1997, 80, 1595-1607
62. Gosfield, E., 3rd; Alavi, A.; Kneeland, B. Comparison of Radionuclide Bone Scans and Magnetic Resonance Imaging in Detecting Spinal Metastases J. Nucl. Med. 1993, 34, 2191-2198
63. Schmidt, G. P.; Schoenberg, S. O.; Schmid, R.; Stahl, R.; Tiling, R.; Becker, C. R.; Reiser, M. F.; Baur-Melnyk, A. Screening for Bone Metastases: Whole-Body MRI Using a 32-Channel System Versus Dual-Modality PET-CT Eur. Radiol. 2007, 17, 939-949
64. Ng, K. K.; Lovell, J. F.; Vedadi, A.; Hajian, T.; Zheng, G. Self-Assembled Porphyrin Nanodiscs with Structure-Dependent Activation for Phototherapy and Photodiagnostic Applications. ACS Nano 2013, doi: 10.1021/nn400418y.
65. 18F]DCFBC: A New Imaging Probe for Prostate Cancer Clin. Cancer Res. 2008, 14, 3036-3043
66. 68Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer J. Med. Chem. 2010, 53, 5333-5341
67. Tavri, S.; Jha, P.; Meier, R.; Henning, T. D.; Muller, T.; Hostetter, D.; Knopp, C.; Johansson, M.; Reinhart, V.; Boddington, S. Optical Imaging of Cellular Immunotherapy against Prostate Cancer Mol. Imaging 2009, 8, 15-26
68. 64Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10- tetraacetic Acid-Quantum Dot-Vascular Endothelial Growth Factor. Molecular Imaging and Contrast Agent Database (MICAD); National Center for Biotechnology Information: Bethesda MD, 2004.
69. Jin, C. S.; Lovell, J. F.; Chen, J.; Zheng, G. Ablation of Hypoxic Tumors with Dose-Equivalent Photothermal, but Not Photodynamic, Therapy Using a Nanostructured Porphyrin Assembly ACS Nano 2013, 7, 2541-2550
70. Liu, T. W.; Chen, J.; Burgess, L.; Cao, W.; Shi, J.; Wilson, B. C.; Zheng, G. Multimodal Bacteriochlorophyll Theranostic Agent Theranostics 2011, 1, 354-362